These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 4009489

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Antipyrine metabolite formation and excretion in patients with chronic renal failure.
    Teunissen MW, Kampf D, Roots I, Vermeulen NP, Breimer DD.
    Eur J Clin Pharmacol; 1985; 28(5):589-95. PubMed ID: 4043202
    [Abstract] [Full Text] [Related]

  • 23. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
    Schellens JH, van der Wart JH, Brugman M, Breimer DD.
    J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
    [Abstract] [Full Text] [Related]

  • 24. Quinidine does not alter antipyrine metabolism.
    Bowles SK, Cardozo L, Edwards DJ.
    J Clin Pharmacol; 1990 Mar; 30(3):267-71. PubMed ID: 2312782
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.
    Eichelbaum M, Ochs HR, Roberts G, Somogyi A.
    Arzneimittelforschung; 1982 Mar; 32(5):575-8. PubMed ID: 7201837
    [Abstract] [Full Text] [Related]

  • 27. Hepatic drug clearance in patients with mild cystic fibrosis.
    Kearns GL, Crom WR, Karlson KH, Mallory GB, Evans WE.
    Clin Pharmacol Ther; 1996 May; 59(5):529-40. PubMed ID: 8646824
    [Abstract] [Full Text] [Related]

  • 28. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
    Bach D, Blevins R, Kerner N, Rubenfire M, Edwards DJ.
    Br J Clin Pharmacol; 1986 Jun; 21(6):655-9. PubMed ID: 3741715
    [Abstract] [Full Text] [Related]

  • 29. Antipyrine pharmacokinetics and urinary excretion in female horses.
    Dyke TM, Sams RA, Hinchcliff KW.
    Am J Vet Res; 1998 Mar; 59(3):280-5. PubMed ID: 9522945
    [Abstract] [Full Text] [Related]

  • 30. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach.
    Schellens JH, Janssens AR, van der Wart JH, van der Velde EA, Breimer DD.
    Eur J Clin Invest; 1989 Oct; 19(5):472-9. PubMed ID: 2511024
    [Abstract] [Full Text] [Related]

  • 31. Effect of concomitant administration of cimetidine and phenobarbital on antipyrine elimination and metabolite formation.
    Sonne J, Døssing M, Poulsen HE, Pilsgaard H, Rasmussen B, Loft S.
    Int J Clin Pharmacol Ther Toxicol; 1987 Apr; 25(4):194-6. PubMed ID: 3583468
    [Abstract] [Full Text] [Related]

  • 32. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.
    Shaw PN, Houston JB, Rowland M, Hopkins K, Thiercelin JF, Morselli PL.
    Br J Clin Pharmacol; 1985 Dec; 20(6):611-8. PubMed ID: 4091993
    [Abstract] [Full Text] [Related]

  • 33. Cimetidine impairs the elimination of theophylline and antipyrine.
    Roberts RK, Grice J, Wood L, Petroff V, McGuffie C.
    Gastroenterology; 1981 Jul; 81(1):19-21. PubMed ID: 7239117
    [Abstract] [Full Text] [Related]

  • 34. Exercise training does not alter cytochrome P-450 content and microsomal metabolism.
    Michaud TJ, Bachmann KA, Andres FF, Flynn MG, Sherman GP, Rodriguez-Zayas J.
    Med Sci Sports Exerc; 1994 Aug; 26(8):978-82. PubMed ID: 7968432
    [Abstract] [Full Text] [Related]

  • 35. The use of single sample clearance estimates to probe hepatic drug metabolism in rats. I.
    Bachmann KA, Yang C, Jahn D, Schwartz J.
    Xenobiotica; 1988 Feb; 18(2):151-9. PubMed ID: 3131969
    [Abstract] [Full Text] [Related]

  • 36. The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.
    Rivière JH, Back DJ, Breckenridge AM, Howells RE.
    Br J Clin Pharmacol; 1985 Nov; 20(5):469-74. PubMed ID: 3878153
    [Abstract] [Full Text] [Related]

  • 37. Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine.
    Sharer JE, Wrighton SA.
    Drug Metab Dispos; 1996 Apr; 24(4):487-94. PubMed ID: 8801065
    [Abstract] [Full Text] [Related]

  • 38. Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol.
    Staiger C, Schlicht F, Walter E, Gundert-Remy U, Hildebrandt R, de Vries J, Wang NS, Harenberg J, Weber E.
    Eur J Clin Pharmacol; 1983 Apr; 25(6):797-801. PubMed ID: 6141054
    [Abstract] [Full Text] [Related]

  • 39. Antipyrine clearance and metabolism in patients with psoriasis.
    Kubota K, Ishizaki T, Chiba K, Takagi A, Nakagawa A, Nakamura K.
    Br J Clin Pharmacol; 1986 Oct; 22(4):455-62. PubMed ID: 3768257
    [Abstract] [Full Text] [Related]

  • 40. Studies on theophylline metabolism: autoinduction and inhibition by antipyrine.
    Denlinger CL, Stryker KK, Slusher LB, Vesell ES.
    Clin Pharmacol Ther; 1987 May; 41(5):522-30. PubMed ID: 3568537
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.